Search

Mailing Lists

SARS-CoV-2 Pseudoviral Particles, Delta Variant (Indian B.1.617.2)

Catalog Number:
SCV2-PsV-Delta
SARS-CoV-2 Pseudoviral Particles, replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (the Indian B.1.617.2 variant). (Mobile users please click "View Full Site" for details)
Price: $500.00
Detailed Description
Keyword: coronavirus, SARS, SARS-Cov, SARS-COV-2, covid19, covid-19, SARS pseudovirus, sars-cov-2 pseudovirus, sars-cov-2 spike, MLV, ace2, B.1.351, covid South Africa variant

SCV2-PsV-Delta

Name

SARS-CoV-2 Pseudoviral Particles, Delta Variant (Indian B.1.617.2)

Description

The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloneymurine leukemia virus (MLV or MuLV) pseudotyped with the SARS-CoV-2 spike protein of the Delta variant (Indian B.1.617.2) (also named 20A/S:478K, VUI-21APR-02) (GISAID accession # EPI_ISL_2020954).
MLV-based virus system is a better choice than HIV-based lentivirus system for making pseudoviral particles in regards of lab safety and product quality. Gag-Pol is the only component from MLV.

Applications

Our Pseudovirus Particles generate robust chemiluminescent signals in cell assays when coupled with our firefly luciferase assay kit (Catalog # CA-L165), useful for 1) screening potential inhibitors to block SARS-CoV-2 entry and viral protein; 2) measuring the activity of and screening for neutralizing antibody against SARS-CoV-2.

Size

5 ml, for one multi-well plate. Pseudoviral particles per mL ~ 1.0E+08

Storage

 -70oC. Shipped on dry ice.

Note

1. Amenable to HTS format (96-well, 384-well and 1536-well format). 
2. HEK293-hACE2 stable cell lines are available seperately (Cat.# CL-hACE2-001, CL-hACE2-002)

For Downloading

  ==>> DATA SHEET       ==>> SAFETY DATA SHEET


Our SARS-CoV-2 pseudovirus products have been tested in many COVID research work. Here are a few citations: 

1) AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo. October 13, 2021.

2) A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes & Infections, May 2021

3) Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. Vaccines, Feb. 2021

4) Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. Clinical Infectious Diseases, Sept. 2020



Related Products

Firefly Luciferase Assay Kit
Starting at $86.00
MLV-Luciferase Pseudoviral Particles
PsV-001
$200.00
SARS-CoV-2 Pseudoviral Particles
SCV2-PsV-001
$400.00
SARS-CoV-2 Pseudoviral Particles, D614G
SCV2-PsV-614G
$500.00
SARS-CoV-2 Pseudoviral Particles, Omicron Variant
SCV2-PsV-Omicron
$500.00
SARS-CoV-2 Pseudoviral Particles, Omicron BA.2 Variant
SCV2-PsV-OmiBA2
$500.00
SARS-CoV-2 Pseudoviral Particles, D614G-A222V
SCV2-PsV-222V
$500.00
SARS-CoV-2 Pseudoviral Particles, D614G-Y453F
SCV2-PsV-453F
$500.00
SARS-CoV-2 Pseudoviral Particles, D614G-N501Y
SCV2-PsV-501Y
$500.00